Increased risk of angioedema w/ ACE inhibitors. Higher frequency of adverse events eg, hypotension, hyperkalaemia & decreased renal function w/ aliskiren. Increased systemic exposure w/ OATP1B1 & OATP1B3 substrates (eg, statins), OAT3 (eg, rifampicin, ciclosporin), OAT1 (eg, tenofovir, cidofovir), MRP2 (eg, ritonavir). Reduced BP w/ PDE5 inhibitors eg, sildenafil. Increased serum K & creatinine w/ K-sparing diuretics, mineralocorticoid antagonists, K-supplements, K-containing salt substitutes, heparin. Increased risk of worsened renal function w/ NSAIDs including selective COX-2 inhibitors. Reversible increased serum lithium conc & toxicity. Reduced Cmax
& AUC of furosemide & metformin. Not to be co-administered w/ another ARB-containing product.